Currently, there is no clinical observation of increased CD38 expression or activity in the context of kidney disease yet; further studies will be needed to confirm the relevance of this NAD+ consumption pathway in the pathogenesis of human renal aging and CKD. The gene discussed is CD38; the disease is chronic kidney disease.